3B BlackBio Dx Limited has successfully concluded its scheduled analyst meeting with Fair Value Capital (India Insight Value Fund) on March 17, 2026. The virtual one-on-one interaction, which began at 4:00 PM, concluded at 4:50 PM, lasting 50 minutes as part of the company's regulatory compliance framework.

Meeting Outcome and Duration

The company formally notified BSE Limited about the successful completion of the analyst meeting through regulatory filing Ref. No.P-66/2025-26/83 dated March 17, 2026. This follows the earlier notification filed under reference P-66/2025-26/82 dated March 12, 2026, which had announced the scheduled meeting.

Information Sharing and Compliance

During the investor meeting, 3B BlackBio Dx Limited reiterated information from its Q3-FY26 investor presentation, which was previously communicated to stock exchanges through reference P66/2025-26/74 dated February 6, 2026. The company emphasized that only publicly available information was discussed, with no unpublished price sensitive information shared with the investor.

The presentation used during the meeting has been made accessible through the company's website at the following link: https://www.kilpest.com/upload/Investors%20Presentation%20February%202026.pdf . This presentation was originally placed before investors after the declaration of financial results for the quarter and nine months ended December 31, 2025.

Regulatory Framework and Documentation

The meeting was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcome communication was digitally signed by Nikhil Kuber Dubey, Whole Time Director (DIN: 00538049), on March 17, 2026 at 4:58 PM, demonstrating the company's commitment to timely regulatory reporting.

3B BlackBio Dx Limited, formerly known as Kilpest India Limited, continues to maintain transparency in its investor relations activities while ensuring strict adherence to regulatory guidelines for information sharing during institutional interactions.

3b blackbio dx Limited has released the transcript of its Q3 FY26 earnings conference call held on February 21, 2026, providing comprehensive insights into the company's financial performance and strategic initiatives following its successful participation at MEDLAB Dubai.

Strong Financial Performance with Coris Integration

The company reported robust nine-month revenue growth, with consolidated figures reaching INR99.06 crores compared to INR64.80 crores in the previous year. The standalone 3B business demonstrated solid growth of 11.8%, which would have been over 20% excluding seasonal fluctuations from dengue and flu outbreaks.

Coris Acquisition Performance and HAT Contract

The Belgium-based Coris acquisition contributed INR24 crores in quarterly revenue, including INR8.8 crores from the one-off HAT (Human African Trypanosomiasis) contract. This contract, originally valued at USD6 million over four years, is expected to continue generating approximately USD1.5 million annually for the next two years.

Market Position and Competitive Landscape

Chairman and Managing Director Dhirendra Dubey highlighted the company's strong market position, commanding 12-15% market share in India's molecular diagnostics reagent market, valued at approximately INR400-500 crores. The company exports to 70 countries, with TRUPCR Europe showing 20%+ growth driven by "Made in UK" credibility.

Strategic Initiatives and Product Development

The company is advancing several strategic initiatives including sample-to-answer machine development through OEM partnerships, automated extraction systems, and highly multiplexed panels for respiratory and AMR testing. The European IVDR certification process is underway for 35-40 key products, representing over 95% of European revenue.

Growth Outlook and Financial Guidance

Management provided guidance for 10-15% overall growth and 15-20% export growth for the current year. The company maintains a cash position of approximately INR190 crores post-Coris acquisition, with INR130-140 crores earmarked for future acquisitions. Two consultants have been appointed to identify acquisition opportunities.

Regulatory and Market Expansion

Coris has initiated US FDA registration processes, expected to complete within 1-2 years, opening access to the substantial US market. The company plans to participate in ADLM USA, showcasing products from all three entities: 3B, TRUPCR Europe, and Coris, targeting Latin American and US distributors.